Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAF^V600-Mutated Melanoma

Clin Cancer Res (2024) 30 (15): 3157–3166.

https://doi.org/10.1158/1078-0432.CCR-23-3171

Published: 01 August 2024

View article titled, A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma

Includes: Supplementary data

Journal Articles

PD-1^T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC

Karlijn Hummelink, Vincent van der Noort, Mirte Muller, Robert D. Schouten, Ferry Lalezari, Dennis Peters, Willemijn S.M.E. Theelen, Viktor H. Koelzer, Kirsten D. Mertz, Alfred Zippelius, Michel M. van den Heuvel, Annegien Broeks, John B.A.G. Haanen, Ton N. Schumacher, Gerrit A. Meijer, Egbert F. Smit, Kim Monkhorst, Daniela S. Thommen

Clin Cancer Res (2022) 28 (22): 4893–4906.

https://doi.org/10.1158/1078-0432.CCR-22-0992

Published: 14 November 2022

View article titled, PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC

Includes: Supplementary data

Journal Articles

From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit

Clin Cancer Res (2022) 28 (5): 831–839.

https://doi.org/10.1158/1078-0432.CCR-21-3238

Published: 03 March 2022

View article titled, From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit

Journal Articles

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

Mehmet A. Bilen, Brian I. Rini, Martin H. Voss, James Larkin, John B.A.G. Haanen, Laurence Albiges, Lance C. Pagliaro, Eric G. Voog, Elaine T. Lam, Nikolay Kislov, Bradley A. McGregor, Aly-Khan A. Lalani, Bo Huang, Alessandra di Pietro, Stan Krulewicz, Paul B. Robbins, Toni K. Choueiri

Clin Cancer Res (2022) 28 (4): 738–747.

https://doi.org/10.1158/1078-0432.CCR-21-1688

Published: 15 February 2022

View article titled, Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

Includes: Supplementary data

Journal Articles

Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4

Oscar Krijgsman, Kristel Kemper, Julia Boshuizen, David W. Vredevoogd, Elisa A. Rozeman, Sofia Ibanez Molero, Beaunelle de Bruijn, Paulien Cornelissen-Steijger, Aida Shahrabi, Martin Del Castillo Velasco-Herrera, Ji-Ying Song, Maarten A. Ligtenberg, Roelof J.C. Kluin, Thomas Kuilman, Petra Ross-Macdonald, John B.A.G. Haanen, David J. Adams, Christian U. Blank, Daniel S. Peeper

Clin Cancer Res (2021) 27 (19): 5389–5400.

https://doi.org/10.1158/1078-0432.CCR-20-4218

Published: 01 October 2021

View article titled, Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4

Includes: Supplementary data

Journal Articles

The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

Isabel C. Poschke, Jessica C. Hassel, Aaron Rodriguez-Ehrenfried, Katharina A.M. Lindner, Ignacio Heras-Murillo, Lena M. Appel, Johanna Lehmann, Tanja Lövgren, Stina L. Wickström, Claudia Lauenstein, Jasmin Roth, Anna-Katharina König, John B.A.G. Haanen, Joost van den Berg, Rolf Kiessling, Frank Bergmann, Michael Flossdorf, Oliver Strobel, Rienk Offringa

Clin Cancer Res (2020) 26 (16): 4289–4301.

https://doi.org/10.1158/1078-0432.CCR-19-3845

Published: 14 August 2020

View article titled, The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

Includes: Supplementary data

Journal Articles

Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry

Clin Cancer Res (2020) 26 (9): 2268–2274.

https://doi.org/10.1158/1078-0432.CCR-19-3322

Published: 01 May 2020

View article titled, Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry

Includes: Supplementary data

Journal Articles

T-Cell Immune Function in Tumor, Skin, and Peripheral Blood of Advanced Stage Melanoma Patients: Implications for Immunotherapy

Esther P.M. Tjin, Debby Konijnenberg, Gabrielle Krebbers, Henk Mallo, Jan W. Drijfhout, Kees L.M.C. Franken, Chantal M.A.M. van der Horst, Jan D. Bos, Omgo E. Nieweg, Bin B.R. Kroon, John B.A.G. Haanen, Cornelis J.M. Melief, Florry A. Vyth-Dreese, Rosalie M. Luiten

Clin Cancer Res (2011) 17 (17): 5736–5747.

https://doi.org/10.1158/1078-0432.CCR-11-0230

Published: 01 September 2011

View article titled, T-Cell Immune Function in Tumor, Skin, and Peripheral Blood of Advanced Stage Melanoma Patients: Implications for Immunotherapy

Includes: Supplementary data

Journal Articles

Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c⁺ Dendritic Cell Frequency Predicts Progression-Free Survival

Hester van Cruijsen, Astrid A.M. van der Veldt, Laura Vroling, Dinja Oosterhoff, Henk J. Broxterman, Rik J. Scheper, Giuseppe Giaccone, John B.A.G. Haanen, Alfons J.M. van den Eertwegh, Epie Boven, Klaas Hoekman, Tanja D. de Gruijl

Clin Cancer Res (2008) 14 (18): 5884–5892.

https://doi.org/10.1158/1078-0432.CCR-08-0656

Published: 14 September 2008

View article titled, Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival

Includes: Supplementary data

Journal Articles

Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8⁺ T-Cell Reactivity in Melanoma Patients

Barbara G. Molenkamp, Berbel J.R. Sluijter, Paul A.M. van Leeuwen, Saskia J.A.M. Santegoets, Sybren Meijer, Pepijn G.J.T.B. Wijnands, John B.A.G. Haanen, Alfons J.M. van den Eertwegh, Rik J. Scheper, Tanja D. de Gruijl

Clin Cancer Res (2008) 14 (14): 4532–4542.

https://doi.org/10.1158/1078-0432.CCR-07-4711

Published: 15 July 2008

View article titled, Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients

Journal Articles

Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response

Astrid A.M. van der Veldt, Martijn R. Meijerink, Alfons J.M. van den Eertwegh, Axel Bex, Gijsbert de Gast, John B.A.G. Haanen, Epie Boven

Clin Cancer Res (2008) 14 (8): 2431–2436.

https://doi.org/10.1158/1078-0432.CCR-07-4089

Published: 15 April 2008

View article titled, Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response

Journal Articles

Tumor-Specific CD8+ T Cell Reactivity in the Sentinel Lymph Node of GM-CSF–Treated Stage I Melanoma Patients is Associated with High Myeloid Dendritic Cell Content

Ronald J.C.L.M. Vuylsteke, Barbara G. Molenkamp, Paul A.M. van Leeuwen, Sybren Meijer, Pepijn G.J.T.B. Wijnands, John B.A.G. Haanen, Rik J. Scheper, Tanja D. de Gruijl

Clin Cancer Res (2006) 12 (9): 2826–2833.

https://doi.org/10.1158/1078-0432.CCR-05-2431

Published: 04 May 2006

View article titled, Tumor-Specific CD8+ T Cell Reactivity in the Sentinel Lymph Node of GM-CSF–Treated Stage I Melanoma Patients is Associated with High Myeloid Dendritic Cell Content

NARROW

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAF^V600-Mutated Melanoma

PD-1^T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC

From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4

The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry

T-Cell Immune Function in Tumor, Skin, and Peripheral Blood of Advanced Stage Melanoma Patients: Implications for Immunotherapy

Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c⁺ Dendritic Cell Frequency Predicts Progression-Free Survival

Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8⁺ T-Cell Reactivity in Melanoma Patients

Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response

Tumor-Specific CD8+ T Cell Reactivity in the Sentinel Lymph Node of GM-CSF–Treated Stage I Melanoma Patients is Associated with High Myeloid Dendritic Cell Content

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only